TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Pharma deals give stocks a lift

A flurry of deals in the pharmaceutical sector helped to shore up global stock markets on Tuesday

The Jakarta Post
London
Tue, April 22, 2014 Published on Apr. 22, 2014 Published on 2014-04-22T22:51:49+07:00

Change text size

Gift Premium Articles
to Anyone

Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
Pharma deals give stocks a lift

A flurry of deals in the pharmaceutical sector helped to shore up global stock markets on Tuesday.

Amid a relative dearth of economic data and the lack of fresh news in Ukraine, investors are focusing on the latest batch of U.S. corporate earnings and the slew of developments in the pharmaceuticals industry.

The already solid backdrop in markets was reinforced by a run of deals among drugmakers. Notably, Switzerland's Novartis unveiled a series of multibillion-dollar deals with Britain's GlaxoSmithKline PLC and the U.S.'s Eli Lilly & Co. that could herald further restructuring in the fast-changing industry.

The deals have come amid a reported takeover attempt of AstraZeneca by Pfizer. And, on Monday Canadian drugmaker Valeant Pharmaceuticals International Inc. said it teamed up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $40 billion.

Analysts said the deals could trigger some further activity in the months ahead.

Drug stocks in Europe and the U.S. have pushed ahead in light of the deals and the mounting speculation over a potential wave of mergers and acquisitions in the sector over the months ahead. GlaxoSmithKline in London, for example, was up 5 percent, partly on the back of the news that it is planning to return 4 billion pounds ($6.7 billion) to shareholders. AstraZeneca was up 5 percent, too, amid the takeover talk.

"It's all kicking off in the pharmaceutical sector," said Louise Cooper of CooperCity.

In Europe, the FTSE 100 index of leading British shares was up 1 percent at 6,691 while Germany's DAX rose 1.9 percent to 9,588. The CAC-40 in France was 1.2 percent higher at 4,483.

On Wall Street, the Dow Jones industrial average was up 0.4 percent at 16,521 while the broader S&P 500 index rose the same rate to 1,879. U.S. stocks have largely recovered their poise over the past few sessions following a run of solid corporate earnings statements, from the likes of Goldman Sachs and Morgan Stanley as well as Netflix.

"Sentiment is boosted, above all, by the generally positive U.S. first quarter earnings results," said Fawad Razaqzada, a technical analyst at Forex.com.

Earlier in Asia, stock markets were less rosy. Tokyo's Nikkei 225 benchmark index fell 0.9 percent to close at 14,388.77 while South Korea's Kospi edged 0.3 percent higher to 2,004.22. Hong Kong's Hang Seng slipped 0.1 percent to 22,730.68 while the Shanghai Composite index advanced 0.3 percent to 2,072.83.

In the currency markets, the mood was fairly flat with the euro steady at $1.3796 and the dollar down 0.1 percent at 102.60 yen. (**)

 

Your Opinion Matters

Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.

Enter at least 30 characters
0 / 30

Thank You

Thank you for sharing your thoughts. We appreciate your feedback.

Share options

Quickly share this news with your network—keep everyone informed with just a single click!

Change text size options

Customize your reading experience by adjusting the text size to small, medium, or large—find what’s most comfortable for you.

Gift Premium Articles
to Anyone

Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!

Continue in the app

Get the best experience—faster access, exclusive features, and a seamless way to stay updated.